Host Response Biomarkers in Acute Fever Syndromes: Clinical Applications and Emerging Evidence

Abstract

Acute fever syndromes represent a significant diagnostic and management challenge in clinical practice, particularly due to the overlapping clinical features of infectious, inflammatory, and non-infectious etiologies. Host response biomarkers have emerged as pivotal tools in differentiating the underlying causes of acute fever, guiding therapeutic decisions, and improving patient outcomes. This review synthesizes current evidence on the utility, mechanisms, and clinical applications of host response biomarkers in acute fever syndromes, discussing their epidemiological impact, pathophysiological basis, diagnostic accuracy, therapeutic implications, recent advances, and guideline recommendations. The review aims to equip clinicians with a comprehensive understanding of biomarker-driven approaches in the management of acute febrile illnesses.

Introduction

Acute fever syndrome, characterized by a sudden elevation in body temperature, is a common presenting complaint among patients in both outpatient and inpatient settings. The differential diagnosis is broad, encompassing bacterial, viral, fungal, and non-infectious inflammatory disorders. Traditional diagnostic methods often lack specificity and require time-consuming laboratory investigations. In light of these challenges, host response biomarkers have gained traction as valuable adjuncts in the rapid evaluation and stratification of patients with acute fever. These biomarkers reflect the host's immune and inflammatory responses, providing insights into disease etiology, severity, and prognosis. This review explores the role and clinical utility of host response biomarkers in acute fever syndromes, with an emphasis on recent advances and evidence-based recommendations.

Epidemiology / Disease Burden

Acute febrile illnesses account for a substantial proportion of emergency department visits and hospital admissions worldwide. In low- and middle-income countries, infectious causes such as malaria, dengue, and typhoid fever predominate, while in high-income settings, respiratory and urinary tract infections are more prevalent. The global burden of acute fever is compounded by the emergence of novel pathogens and the resurgence of vector-borne diseases. Unnecessary antimicrobial usage, driven by diagnostic uncertainty, contributes to antimicrobial resistance and increased healthcare costs. The integration of host response biomarkers into clinical practice has the potential to address these challenges by facilitating precise and timely diagnosis, thereby reducing morbidity, mortality, and resource utilization.

Pathophysiology

The pathophysiology of acute fever involves a complex interplay between the host immune system and pathogenic or non-infectious triggers. Fever is primarily mediated by the release of pro-inflammatory cytokines such as interleukin-1 (IL-1), IL-6, and tumor necrosis factor-alpha (TNF-α), which act on the hypothalamic thermoregulatory center. Host response biomarkers, including C-reactive protein (CRP), procalcitonin (PCT), and various cytokines, are produced in response to these mediators and reflect the underlying inflammatory milieu. The specificity and kinetics of biomarker production vary depending on the etiology; for example, PCT is more closely associated with bacterial infections, whereas viral infections may elicit elevations in interferons and other distinct cytokines. Understanding these mechanisms is crucial for the interpretation and clinical application of biomarker assays in acute fever syndromes.

Risk Factors

Numerous patient- and disease-related factors influence the host response and biomarker profiles in acute fever syndromes. Immunocompromised states, such as HIV infection, malignancy, or immunosuppressive therapy, may attenuate typical biomarker responses, complicating diagnostic interpretation. Age, comorbidities, and genetic predispositions also modulate the magnitude and duration of biomarker elevations. Additionally, the timing of sample collection relative to fever onset and prior antimicrobial therapy can impact biomarker levels. Clinicians must consider these variables when integrating biomarker data into the diagnostic and management process.

Clinical Features

Acute fever syndromes present with a spectrum of clinical manifestations, ranging from isolated fever to severe sepsis or multi-organ dysfunction. The clinical features alone often do not reliably distinguish between infectious and non-infectious etiologies. Host response biomarkers offer an objective adjunct to clinical assessment, aiding in the identification of bacterial versus viral infections, systemic inflammation, and prognostic stratification. For instance, elevated PCT levels are suggestive of bacterial infection and correlate with disease severity, while persistently raised CRP may indicate ongoing inflammation or complications. Integration of biomarker trends with clinical presentation enhances diagnostic accuracy and optimizes patient care.

Diagnosis

The diagnostic utility of host response biomarkers in acute fever syndromes lies in their ability to discriminate between various etiologies and guide further investigations. CRP and PCT are the most widely studied and utilized biomarkers in this context. Meta-analyses have demonstrated that PCT outperforms CRP in distinguishing bacterial from viral infections, particularly in respiratory and systemic infections. Emerging biomarkers such as presepsin, soluble triggering receptor expressed on myeloid cells-1 (sTREM-1), and host gene expression signatures show promise in improving diagnostic precision. Multiplex biomarker panels and point-of-care platforms are increasingly available, enabling rapid bedside assessment. However, no single biomarker is definitive, and interpretation should be contextualized within the clinical scenario and pre-test probability.

Treatment & Management

Host response biomarkers play a critical role in the therapeutic decision-making process for patients with acute fever syndromes. Biomarker-guided algorithms have been shown to reduce unnecessary antibiotic use, particularly in lower respiratory tract infections and sepsis, without compromising patient safety. Serial measurement of CRP or PCT can inform the duration of antimicrobial therapy and monitor treatment response. In addition to guiding antimicrobial stewardship, biomarkers may also identify patients at high risk of complications who warrant closer monitoring or escalation of care. Integration of biomarker data into multi-disciplinary care pathways enhances individualized patient management and resource allocation.

Recent Advances / Emerging Therapies

Recent advances in omics technologies and systems biology have propelled the discovery of novel host response biomarkers and gene expression signatures. Transcriptomic and proteomic profiling have identified host gene signatures capable of distinguishing bacterial from viral infections with high accuracy. Machine learning algorithms applied to multi-biomarker data are being developed to enhance diagnostic and prognostic stratification. Point-of-care molecular platforms enable rapid, bedside assessment of complex biomarker panels, facilitating early intervention. Ongoing research is focused on the validation and clinical integration of these emerging tools, with the goal of achieving precision medicine in the management of acute fever syndromes.

Guideline Recommendations

International guidelines, including those from the Infectious Diseases Society of America (IDSA) and the Surviving Sepsis Campaign, endorse the adjunctive use of biomarkers such as PCT in the evaluation of acute fever and suspected sepsis. Guidelines recommend interpreting biomarker results in conjunction with clinical assessment and other diagnostic modalities. Biomarker-guided antimicrobial stewardship strategies are recommended for selected patient populations, particularly in the context of respiratory infections and sepsis. Ongoing updates to guidelines are anticipated as new evidence and technologies emerge, emphasizing the importance of clinician education and multidisciplinary collaboration in biomarker-based care.

Conclusion

Host response biomarkers are invaluable tools in the diagnosis, risk stratification, and management of acute fever syndromes. Their integration into clinical practice has the potential to improve diagnostic accuracy, optimize antimicrobial use, and enhance patient outcomes. Ongoing research and technological advancements continue to expand the biomarker repertoire and clinical applications. Clinicians must remain informed of current evidence, guideline recommendations, and practical considerations to maximize the benefits of biomarker-driven approaches in the care of patients with acute fever syndromes.